Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are correct in that it is not an immediate concern of Ipix, but if the clinical trials for Covid19 are positive more eyes will be looking at Ipix.
Some of the biggest of those eyes will not only want Brilacidin but they will want to make other definsins mimetics to treat all sorts of conditions.
Polymedix did many preclinical studies on a variety of difficult to treat infectious diseases such as multiple resistant Klebsiella, Tuberculosis. Malaria. Candida alba, Muliple gram negative compounds and multiple fungal diseases.
They even designed a drug to counter act heparin.
With DeGrado as IPIX's scientific advisor developer of defensin mimetics and a
leading expert on protein function the sky is the limit on the type of pharmaceuticals which potentially can be developed.
Jmo, Farrell
Thanks for the link. I can not find any report from the Remdesivir RBL studies. Gilead had other preclinical test performed, but the RBL studies were the only independent studies I could find.
If we can not find a report it would be fair to conclude both Gilead and the RBL signed NDA and one of them, IMO most likely Gilead, did not want the results released.
The silence is deafening.
Glta, Farrell
The number depends on who you read:
GLTA,Farrell
MD Anderson
What does it take to achieve herd immunity?
That varies by disease. For this particular coronavirus, doctors estimate that about 60% to 70% of the human population would need to have antibodies in order to have herd immunity as a species.
https://www.mdanderson.org/cancerwise/what-is-covid-19-coronavirus-herd-immunity-when-will-we-achieve-herd-immunity.h00-159383523.html
John Hopkins School of Public Health
What is herd immunity?
When most of a population is immune to an infectious disease, this provides indirect protection—or herd immunity (also called herd protection)—to those who are not immune to the disease.
For example, if 80% of a population is immune to a virus, four out of every five people who encounter someone with the disease won’t get sick (and won’t spread the disease any further). In this way, the spread of infectious diseases is kept under control. Depending how contagious an infection is, usually 70% to 90% of a population needs immunity to achieve herd immunity.
https://www.jhsph.edu/covid-19/articles/achieving-herd-immunity-with-covid19.html
Mayo clinic
Even if infection with the COVID-19 virus creates long-lasting immunity, a large number of people would have to become infected to reach the herd immunity threshold. Experts estimate that in the U.S., 70% of the population — more than 200 million people — would have to recover from COVID-19 to halt the epidemic. If many people become sick with COVID-19 at once, the health care system could quickly become overwhelmed. This amount of infection could also lead to serious complications and millions of deaths, especially among older people and those who have chronic conditions.
https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/herd-immunity-and-coronavirus/art-20486808
THe English...University of Nottingham
Mathematicians from the University of Nottingham and University of Stockholm devised a simple model categorising people into groups reflecting age and social activity level. When differences in age and social activity are incorporated in the model, the herd immunity level reduces from 60% to 43%. The figure of 43% should be interpreted as an illustration rather than an exact value or even a best estimate.
https://investorshub.advfn.com/secure/post_reply.aspx?message_id=157928604
I neglected to consider the more benign Coronavirus which causes URIs. Of course that assume long lasting immunity fo a different genotype which may not be the case.
Glta, Farrell
Unfortunately the "waves" are hitting the country at different times. As soon as it dies down it one area,, a different one will turn "red" again.
The reason may be when the virus is increasing it scares the crap out of people and the compliance with mitigation increases. Then when an area cools off the the compliance decreases and the cases increase.
I am skeptical that this will disappear like MERS or SARS. It is too contagious. The 1917-1918 influenza pandemic maybe a good model, but that means 2 years duration if no treatment or vaccine is approved.
One truth from the very beginning has been no one has been able to predict anything accurately about Covid 19 including the course of the pandemic. The worse possiblity is the virus may be active until we have a "herd immunity" where 60%-70% of the population has been infected which will mean millions of more deaths and complications.
GLTA Farrell
Dr DeGrado has been extremely successful. He heads the Degrado Institute at the University of San Francisco. The Degrado Institute is involved with scores of research projects which primarily deal with protein science. Dr DeGrado is an international expert in his field.
It is almost unheard of for a scientist of his standing to take on a position with a small company like IPIX. Usually individuals in his position will recommend an associate or a younger researcher. The fact he has accepted the position at IPIX is a complement to Leo Ehrlich and IPIX as well as a validation of Brilacidin's science.
Having a world renown scientist to guide Brilacidin through the clinical trials will help Brilacidin in every way. Dr DeGrado's connections are international in scope with universities,government and industry. A tenured scientist such as Dr DeGrdo is not looking for opportunities to fail. He has taken on the position as Brilacidin's science advisor for one reason; he wants to be part of the team that develops Brilacidin as a Covid 19 treatment.
GLTA,Farrell
Great point. If big pharma ever wants to partner with IPIX Brilacidin will be an important part of the package, but a bigger part will be the expertise to develop new defensin mimetics and Dr DeGrado and IPIX's computer software will be a key.
IMO defensin mimetics development could be as big as the development of monoclonal antibodies and Degrado and the other Polymedix scientist could be on the level of Niels K. Jerne, Georges J.F. Köhler and César Milstein who won the Nobel Prize "for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies".
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445/
https://www.whatisbiotechnology.org/index.php/exhibitions/milstein/legacy/The-legacy-of-Milsteins-work
If Brilacidin becomes a standard treatment for
covid19, DeGrado is a lock for a Nobel Prize.
JMO
GLTA,Farrell
I agree. The stars are aligning for Brilacidin.
The future is bright
GLTA,Farrell
DeGrado has been mentoring Phd candidates his whole career. Now these bright people will have achieved success through out the country. He will have contacts in government, HHS, NIAID, DOD , FDA universities, industry and pharma companies which will help propel Brilacidin to the next level.
Glta,Farrell
IPIX has been planning human clinical trials for weeks. I expect this momentum will continue to the announcement of IND, hiring CRO,clinical sites and the beginning of clinical trials.
Clear sailing for as far as I can see.
GLTA,Farrell
Wow!!! Dr DeGrado's association just confirms and validates Brilacidin's accomplishments.
Isn't it terrific to have one of the worlds leading scientists to be on our team?
What's next? Nobel Prize nomination for Dr DeGrado?
Good luck, Farrell
Dr DeGrado did more than discover Brilacidin; he created and improved it to be be more pharmacologically active with broader antibiotic [and now antiviral] effects as well as improved pharmocodynamics and stability.
He is the father of defensin mimetics and Brilacidin. Now that Brilacidin is being further validated you can expect more research into other defensin mimetics.
The best news is IPIX owns the defensin mimetic playbook...the computer program used to develop defensin mimetics.
GLTA Farrell
https://www.globenewswire.com/news-release/2020/08/26/2084130/0/en/Dr-William-F-DeGrado-a-Discoverer-of-Brilacidin-Joins-Innovation-Pharmaceuticals-as-Scientific-Advisor.html
The PHRI is supposed to study some of Brilacidin's immunologic effects. IMO these studies will be featured in one of the peer review articles, but no definitive conformation of that has been issued by the company.
Polymedix did a variety of screening tests for immunologic benefits of Brilacidin. To the best of my knowledge this data has never been released , but it has been frequently referenced.The IBD studies also referred to immunologic benefits of Brilacin One of the proposed mechanism was replacement of diminished GI Paneth cell defensins, but again I do not believe the data was published.
The peer review article, which should be released in the next couple of weeks; hopefully, will have a thorough review of the data supporting the immunologic effects of Brilacidin
"Scientists at the Public Health Research Institute plan to evaluate Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators (peripheral blood mononuclear cells, T cells, B cells, monocytes, macrophages) obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus. Brilacidin drug substance has been received by the Institute and is now available for testing."
"Additional pre-clinical and clinical data support Brilacidin’s potential to inhibit the production of IL-6, IL-1b, TNF-a and other pro-inflammatory cytokines and chemokines (e.g., MCP-1), which have been identified as central drivers in the worsening prognoses of COVID-19 patients. "
http://www.ipharminc.com/press-release/2020/5/5/inhibitory-effect-of-innovation-pharmaceuticals-brilacidin-on-sars-cov-2-covid-19-in-primary-human-immune-cells-to-be-studied-at-leading-public-health-research-institute
The news is getting out. Thanks for posting.
GLTA Farrell
The fact that Brilacidin is showing success against Covid gives hope to those studying other viral disorders but the results are not transferable and would have to be repeated against every different virus.
If Brilacidin is successful in its clinical trials I believe it will be tested as an inhaler, but that should be years away. If it is successful as an inhaler I expect it will be studied in a whole series of pulmonary disorders asthma,COPD, bronchitis,cystic fibrosis, bronchiectasis, pulmonary fibrosis and perhaps others.
GLTA,Farrell
The number is excellent.It is a measure of relative potential as an antiviral pharmaceutical and is used by scientists and industry.
I am surprised at the lack of enthusiasm for the report, but I am not disappointed. This is the first of many news releases we can expect in the next few weeks as IPIX plans for human clinical trials.
The peer review pre print publication release will occur soon and should include additional Brilacidin data.Then you can expect a whole series of PR's related to the planned clinical trials.
IMO eventually the IPIX share price is going to catch up with its scientific achievements.Every positive test lowers the risk of owning IPIX stock. The bottom line is success in the clinical trials. The more good news now the more likely Brilacidin will succeed in clinical trials.
1oldpof said it best in post 320293
"The actual efficacy will be revealed in clinical trials. Our “leadership’s” latest political move with convalescent serum is definitely not the answer. As for vaccines, in my opinion, long ways off. Therapeutics are the way to go and B will show its stuff in the clinic, despite the opinions of “shareholders” looking for quick gains. Today was a very very good day."
GLTA Farrel
Close at HOD .30. Good volume. Every reason to buy with this news.
Can not keep this dog under the porch any longer.
GLTA,Farrell
Today's PR is on Ameritrade now.
GLTA Farrell
I agree we are going to see new buyers due to the excellent SI number. Look for an increasing volume and buying as the week progresses.
Good luck to all, Farrell
Hopefully the genetic differences between individuals which leads to such a wide variation in clinical manifestions in covid19 will be discovered.
Perhaps it will start with the animal research. The connection between these animals is not obvious.
Thanks for posting, Farrell
SARAS -Bats Civet cats
MERS- Camels
Covid19 Deer mice
Then throw in Bats and Pangolins
No, both Regeneron's monoclonal antibody and Brilacidin attach to the S protein to block viral entry into the cell. Regeneron claims its antibody blocks it at multiple sites so that could increase efficay.
Brilacidin has 2 additional MOAs. It is virucidal by opening a pore in the viral outer coat which results in rapid viral destruction. In addition Brilacidin blocks the main protease to prevent viral replication.
Brilacidin's 3 MOA's plus its virucidal effect makes it unique. If I was Regeneron, I would worry more about Brilacidin than vice versa.
Good luck,Farrell
IMO Remdesivir is done. It is possible Brilacidin could be combined with Regeneron's monoclonal antibody drug which it is pushing through clinical trials. Regeneron's PR stats their drug attaches to the S protein to prevent attachment to the cell. They state they will have data from their clinical trial in September.
It is possible it could have synergies with Brilacidin's 3 mechanisms of action.
Good luck,Farrell
WHO director general Tedros Adhanom Ghebreyesus has as much credibility as Baghdad Bob.
The truth is this virus is unknown and its biologic course remains uncertain.Extrapolating the disease course of the Spaniish flu to Coravirus is just a sign of desperation from the man who was completely misled by the Chinese and is accused of trying to cover up cholera epidemics in his own country.
https://www.theglobeandmail.com/world/article-questions-surfacing-about-history-of-whos-director-tedros-adhanom/
https://foreignpolicy.com/2020/04/02/china-coronavirus-who-health-soft-power/
It is much more contagious with many more deaths than the previous coronavirus epidemics, SARS and MERS. SARS and MERS had much higher mortality rate, but were localized geographically and much easier to contain. They both had animal hosts which Covid 19 may or may not have.
IMO no one can accurately guess the course of Covid19. Its rate of person to person spread is alarming and has allowed spread to the far reaches of the globe. Once it diminishes in one area, it reignites in another.
Covid19 is different from any known viral epidemic. The best course of action is to continue to push forward with research for treatment and vaccines
GLTA Farrell
The way I visualize Brilacidin's MOAs:
Once the drug enters the circulation it can destroy the virus on contact by attaching to and penetrating the viral coating or capsid.This opens a pore in the coating and results in the destruction of the virus. This virucidal MOA rapidly destroys the virus. This may be the most important MOA and Briliacidn seems to be the only Coronvirus antiviral being studied with this unique MOA.
Any virus that escapes is blocked from entering cells by Brilacidin's ability to bind the viral S or spike protein from attaching to the cell wall ACE protein which seems to be Coronavirus's only point of entry.
When cells are infected the virus hijacks the cells intracellular processes to manufacture more virus. Brilacidin has the ability to enter the infected cells and attach to and deactivate the viral main protease which is one of the key viral components to begin viral replication. Most antivirals, eg Remdesivir, work by only blocking viral reproduction as nucleic base analogues which are incorporated into the viral RNA [ or DNA in DNA viruses] and prevent RNA replication for the new viruses.
Brilacidin's theoretic advantages over other treatments are it quickly reduces the viral "load" which should reduce the severity of illness and the systemic complications. Its triple mechanism of action will make viral resistance much more difficult and make Brilacidin more active against mutated viruses which seem to be emerging.By destroying the virus at an early stage it will release viral antigens into the circulation which which will recruit the immune system to attack the virus. The immunomodulating abilities may prevent the immune system from over reacting and causing the Cytokine storm and ARDS which has resulted in the severe lung complications. Pulmonary failure is the most common cause of death in Covid19.Its broad spectrum antibiotic abilities will reduce secondary bacterial complications in the severely ill patients
The RBL and past ABSSSI studies suggest Brilacidin could be a superior antiviral which may have many advantages over current treatments in terms of reducing mortality and complications.It appears to be a much safer drug.
An effective anti viral will be an essential part of any treatment plan for Covid19. Remdesivir has not been able to show it can reduce mortality or complications so the bar for Brilacidin's success is very low.
Hopefully Brilacidin can break the strangle hold the pandemic has on the health, economy and psyche of the country and world.
The next few weeks should be exciting times for IPIX long term investors.
Good luck,Farrell
China COVID 19: The chimera that changed the world
I was looking for an English translation to buy. It does not appear to be available.
My Italian is a little rusty.
Good luck, Farrell
If you believe facts outside the approved rhetoric are not suppressed in every way conceivable; even you could be called very naive.
GLTA Farrell
Fact checkers deny Fauci or NIH employees will personally benefit from the Moderna vaccine.The NIH does hold a substantial amount of the vaccine rights.
If you are a Moderna stockholder you should question the real value of your stock if the NIH can license the rights to the vaccine to anyone it wants any where in the world for any price which is my inference from the last statement , but that may not be entirely correct.
NIH added that "federal employees listed as inventors on these patent applications assigned their rights to the U.S. government. Accordingly, should the [United States Patent and Trademark Office] and other national patent authorities grant the patents, the U.S. government will hold ownership interest in the patents."
Rizvi said co-owning the vaccine could allow NIH to more broadly license the underlying technology to other vaccine manufacturers "without the consent of Moderna," a company that is valued at $25 billion despite having no federally approved drugs on the market.
Creepy, slimey, inappropriate to post the CEO's personal information on an investing board. I hope this post as well as the original are deleted.
Good luck, Farrell
I tried to buy the book. Guess what I could not find it for sale anywhere. No sign of an English edition. Its not listed on Amazon or Barnes and Noble. I Googled the title and author no luck.
If anyone can find it please let me know.
What happened to free speech? The US is starting to feel more like the Gulag Archipelago every freaking day.
Thanks for posting. Great stuff.
GLTA Farrell
If you read and understand the IPIX PRs from 2/18 forward you will see a progressive volume of scientific evidence which shows Brilacidin has impressive in vitro action against Covid 19.
Imo this should lead to human clinical trials, funding and even partnerships to quickly expedite the study of Brilacidin as an antiviral against Covid 19.
Of course we will not know where Brilacidin finds its place as a Covid 19 treatment until the clical trials are finished, but the independent studies done in the RBL labs have been undeniable to those who are
reviewing the data critically and without
other agendas.
Glta, Farrell
The longer we wait the bigger the news.
JMO... and my IPIX ESP
GLTA, Farrell
Makes one wonder if its not the first step in a much bigger deal.
GLTA,Farrell
I agree. With the RBL study ending in August we should have a lot of news to be released in the next few weeks. I suspect Leo knows most of the RBL results.I would expect he will release some next week
sometime in the next few weeks we could hear:
-SI for Brilacidin
-Comparison SI level for Brilacidin and Remdesivir
-Study of Brilacidin and Remdesivir combination for possible synergy
-Toxicity studies for Remdesivir and Brilacidin
-More dosage information for Brilacidin
-Confirmation of Brilacidin's anti inflammatory effects and mechanisms of the immunomodulation {from PHRI}
-Preprint peer review studies
-End of in vitro trial of Brilacidin summary with data
-Details of Mechanism of Action including virucidal, anti attachment and anti replication
-Plans for human clinical trials
-Increased staffing at IPIX for clinical trials or CRO
-Clinical trial location
-Confirmation of IV Brilacidin ready for clinical trials
-CDMO report
-Human clinical trial design
-Future studies for other viruses eg Encephalitis, SARS, MERS and others as a broad spectrum antiviral
-Additional RBL studies
-Funding
and I am sure a few surprises
It is an exciting time to be invested in IPIX
Good luck to all, Farrell
Convalescent Plasma Associated with Reduced COVID-19 Mortality in 35,000-Plus Hospitalized Patients
article preprint
https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1
Unusual report of large study, not a clinical trial, with convalescent plasma given at least once to Covid19 patients with severe symptoms or high risk. No attempt was made to standardize the study in any way such as stage of disease, frequency of administration, duration of treatment.
My interpretation of the FDA coordinated study was since serum immunoglobulin treatments are standard for many autoimmune and infectious disorders doctors have been giving the treatments for Covid 19 without peer review proof of efficacy. IMO this was the first step by the FDA to form a diverse study group to not only encourage the treatments ,but to lay the ground work for future studies.I would expect big pharma to develop proprietary serum products with enhanced levels of anti coronavirus antibodies.
IMO this lays the ground work for every severely ill Covid19 patient to receive Convalescent Plasma early in the course of the disease along with Remdesivir [for now}and Dexamethasone.
GLTA Farrell
PS I hope Brilacidin's preprint will have more impact than this one.
Since the RBL's are administratively directly under Dr Fauci's NIAID I think he would know it before we do.
GLTA, Farrell
Great post...agree
Farrell
Regeneron earned most of it's good will with its Ebola drug.
We will see how the market views Brilaidin and its science over the next few weeks as the final RBL reports are released.
My bet is the remaining RBL data will confirm the testing done to date and Brilacidin will begin a quick human clinical trial.
You are right to be cautious. We will not know for sure until the final reports are released
Glta, Farrell
No, Dr Fauci and Trump would take full credit for it and embrace it like a new grandchild.
A high SI would signal scientists, pharmaceutical leaders, and politicians to Brilacidin's potential.
If Brilacidin is clearly superior plus safe and effective in human trials it will be pushed forward with expedited human trials and hopefully an EUA.
It would be the truth that could not be swept under the rug.
Covid 19 is an international emergency. Politics will not hold it back. Covid's effects on health,the economy ,international geopolitics, domestic unrest,unemployment, income disparity, demise of small businesses and the travel industry, not to mention the upcoming election will not be ignored
Remdesivir would be tossed aside like yesterdays newspaper.
JMO Farrell
Thanks for posting. New information [to me} regarding Sequens pathway for biosynthesis of Brilacidin.
I wonder if they are associated with or work with Evonik ?
If not, what is the connection to IPIX?
GLTA, farrell